Biomarin Pharmaceutical (BMRN) Enterprise Value (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Enterprise Value data on file, last reported at -$2.2 billion in Q1 2026.

• Quarterly Enterprise Value fell 74.67% year-over-year to -$2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 74.67% YoY) and the FY2025 annual result came in at -$1.6 billion, down 37.17% from the prior year.
• Enterprise Value slipped to -$2.2 billion in Q1 2026, from -$1.6 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$930.4 million in Q3 2024 to a low of -$2.2 billion in Q1 2026.
• A 5-year average of -$1.3 billion and a median of -$1.2 billion in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value climbed 17.36% — and 2026, when it plunged 74.67%.
• Tracing BMRN's Enterprise Value over 5 years: stood at -$1.3 billion in 2022, then rose by 16.86% to -$1.1 billion in 2023, then dropped by 5.95% to -$1.1 billion in 2024, then sank by 37.17% to -$1.6 billion in 2025, then sank by 42.41% to -$2.2 billion in 2026.
• The last three Enterprise Value figures came in at -$2.2 billion (Q1 2026), -$1.6 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.